Aktis Oncology pairs a differentiated Actinium-225 miniprotein platform and cash-funded runway with high-stakes clinical catalysts, creating substantial upside potential but binary clinical and supply-chain risk.
Overview
Aktis Oncology is a Boston-based clinical-stage biotechnology company developing miniprotein radioconjugates for solid tumors. Its approximately 10–15 kDa scaffolds are paired primarily with Actinium-225 to seek deep tumor penetration, rapid systemic clearance, and localized alpha-particle DNA damage. Revenue currently comes exclusively from research collaborations, principally Eli Lilly’s May 2024 agreement, which included $60 million upfront, up to $1.1 billion in milestones, and tiered royalties. The company went public in January 2026, raising $365.4 million gross. Its lead assets are AKY-1189, in Phase 1b for Nectin-4-expressing cancers and granted FDA Fast Track status for mUC in February 2026, and AKY-2519, in Phase 1b trials for mCRPC, NSCLC, and other solid tumors. Q2 2026 revenue was $3.384 million, up 111.5% year over year and above consensus, while net loss was $24.144 million and diluted EPS was -$0.44. **Cash of $517.32 million and no reported debt support a runway into 2029.** At $18.00 per share, estimated enterprise value is approximately $450 million; cash represents $9.62 per share. Wall Street targets are $33–$40. **The key near-term catalyst is preliminary AKY-1189 Phase 1b data expected in Q1 2027**, alongside AKY-2519 trial expansion and Lilly milestones.